ALEC:NSD-Alector Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 15.54

Change

0.00 (0.00)%

Market Cap

USD 1.26B

Volume

0.54M

Avg Analyst Target

USD 33.00 (+112.36%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Alector Inc (ALEC) Stock Analysis:
Based on the Alector Inc stock forecasts from 2 analysts, the average analyst target price for Alector Inc is USD 33.00 over the next 12 months. Alector Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alector Inc is Slightly Bearish, which is based on 1 positive signals and 2 negative signals. At the last closing, Alector Inc’s stock price was USD 15.54. Alector Inc’s stock price has changed by -1.97% over the past week, -8.18% over the past month and -6.33% over the last year.

About

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementi ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-23 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD57.99B 27.35 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD35.77B 4.66 5.67
BGNE BeiGene Ltd

N/A

USD25.75B N/A N/A
SGEN Seagen Inc

N/A

USD23.32B 55.02 44.86
GMAB Genmab A/S

N/A

USD22.58B 51.93 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

N/A

USD16.81B 20.32 11.89

ETFs Containing ALEC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.75% 32% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.75% 32% F 16% F
Trailing 12 Months  
Capital Gain -6.33% 87% B+ 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.33% 87% B+ 50% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 11.98% 52% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.98% 52% F 54% F
Risk Return Profile  
Volatility (Standard Deviation) 43.62% 67% D+ 39% F
Risk Adjusted Return 27.46% 57% F 45% F
Market Capitalization 1.26B 84% B 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.22 25% F 24% F
Price / Cash Flow Ratio -7.58 62% D- 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -10.18% 89% B+ 39% F
Return on Invested Capital -84.44% 25% F 9% F
Return on Assets -3.08% 90% A- 38% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 9.52 10% F 6% F
Short Percent 12.20% 13% F 13% F
Beta 1.07 59% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.